Ribavirin small-particle-aerosol treatment of influenza B virus infection

Antimicrob Agents Chemother. 1988 May;32(5):761-4. doi: 10.1128/AAC.32.5.761.

Abstract

In a randomized double-blind trial of aerosolized ribavirin for the treatment of influenza B virus infection, no significant difference was found in the febrile course or symptom score of the ribavirin-treated versus placebo-treated patients. The apparent lack of efficacy in this study as compared with that in previous studies is unexplained.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aerosols
  • Body Temperature
  • Clinical Trials as Topic
  • Disease Outbreaks*
  • Double-Blind Method
  • Humans
  • Influenza B virus / growth & development
  • Influenza, Human / drug therapy*
  • Random Allocation
  • Ribavirin / administration & dosage
  • Ribavirin / therapeutic use*
  • Ribonucleosides / therapeutic use*

Substances

  • Aerosols
  • Ribonucleosides
  • Ribavirin